Silo Pharma (SILO) Stock: Buy, Sell, or Hold?
SILO - Silo Pharma, Inc. Common Stock
$1.46
-0.04 (-2.80%)
▼
5d:
-16.69%
30d:
-41.68%
90d:
-76.56%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When SILO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SILO is down 16.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SILO is down 16.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SILO is currently trading at $1.46, which is considered oversold relative to its 30-day fair value range of $1.66 to $2.40.
Technical Outlook: Technically, SILO is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SILO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+585.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SILO is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SILO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+585.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.66 -
$2.40
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 585.9% below Wall St target ($10.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.66 -
$2.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.45
Resistance Level
$1.84
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Wall Street Target
$10.00
(+585.9%)
Share & Embed Analysis
Last updated: October 03, 2026 12:10 PM ET
Data refreshes hourly during market hours. Next update: 1:10 PM
Data refreshes hourly during market hours. Next update: 1:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SILO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
